Wilson BE - Search Results

1

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.

Desnoyers A, Nadler M, Wilson BE, Stajer S, Amir E. Desnoyers A, et al. Among authors: wilson be. NPJ Breast Cancer. 2022 Mar 31;8(1):43. doi: 10.1038/s41523-022-00405-1. NPJ Breast Cancer. 2022. PMID: 35361769 Free PMC article.

2

A critique of the fragility index.

Desnoyers A, Nadler MB, Wilson BE, Amir E. Desnoyers A, et al. Among authors: wilson be. Lancet Oncol. 2019 Oct;20(10):e552. doi: 10.1016/S1470-2045(19)30583-2. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31578994 No abstract available.

3

Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours.

Desnoyers A, Wilson BE, Nadler MB, Amir E. Desnoyers A, et al. Among authors: wilson be. Cancer Treat Rev. 2021 Mar;94:102167. doi: 10.1016/j.ctrv.2021.102167. Epub 2021 Feb 16. Cancer Treat Rev. 2021. PMID: 33652263 Review.

4

Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact.

Wilson BE, Jacob S, Do V, Amir E, Bray F, Ferlay J, Knaul FM, Elawawy A, Pearson SA, Barton MB. Wilson BE, et al. JCO Glob Oncol. 2021 Jun;7:1074-1083. doi: 10.1200/GO.21.00028. JCO Glob Oncol. 2021. PMID: 34228485 Free PMC article.

5

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.

Wilson BE, Desnoyers A, Nadler MB, Tibau A, Amir E. Wilson BE, et al. Cancer Med. 2021 Aug;10(16):5405-5414. doi: 10.1002/cam4.4029. Epub 2021 Jul 28. Cancer Med. 2021. PMID: 34323019 Free PMC article.

6

Resource stratified guidelines for cancer: Are they all the same? Interguideline concordance for systemic treatment recommendations.

Wilson BE, Elliott MJ, Pearson SA, Amir E, Barton MB. Wilson BE, et al. Int J Cancer. 2022 Jan 1;150(1):91-99. doi: 10.1002/ijc.33764. Epub 2021 Aug 25. Int J Cancer. 2022. PMID: 34398966

7

Patient and provider determinants of breast cancer screening among Ontario women aged 40-49: a population-based retrospective cohort study.

Nadler MB, Ivers N, Marchand-Austin A, Lofters A, Austin PC, Wilson BE, Desnoyers A, Amir E. Nadler MB, et al. Among authors: wilson be. Breast Cancer Res Treat. 2021 Oct;189(3):631-640. doi: 10.1007/s10549-021-06344-y. Epub 2021 Aug 19. Breast Cancer Res Treat. 2021. PMID: 34414531

8

Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials.

Wilson BE, Nadler MB, Desnoyers A, Amir E. Wilson BE, et al. J Natl Compr Canc Netw. 2021 Sep 3;19(12):1433-1440. doi: 10.6004/jnccn.2021.7015. J Natl Compr Canc Netw. 2021. PMID: 34479210

9

Prioritising access to cancer drugs.

Elliott MJ, Amir E, Pearson SA, Barton MB, Wilson BE. Elliott MJ, et al. Among authors: wilson be. Lancet Oncol. 2022 Jan;23(1):e1. doi: 10.1016/S1470-2045(21)00641-0. Lancet Oncol. 2022. PMID: 34973219 No abstract available.

10

A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time.

Wilson BE, Desnoyers A, Al-Showbaki L, Nadler MB, Amir E. Wilson BE, et al. Sci Rep. 2022 Apr 15;12(1):6352. doi: 10.1038/s41598-022-09949-5. Sci Rep. 2022. PMID: 35428842 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters